BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 25642591)

  • 21. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
    Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
    Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
    Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
    Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis.
    Michalaki M; Bountouris P; Roupas ND; Theodoropoulou A; Agalianou N; Alexandrides T; Markou K
    Hormones (Athens); 2016 Oct; 15(4):511-517. PubMed ID: 28222412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
    Sacks W; Wong RM; Bresee C; Braunstein GD
    Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
    Llamas-Olier AE; Cuéllar DI; Buitrago G
    Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.
    Jeon YW; Ahn YE; Chung WS; Choi HJ; Suh YJ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e167-73. PubMed ID: 24289279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
    Chandekar KR; Satapathy S; Bal C
    Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
    Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
    Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?
    Han K; Noh HM; Jeong HM; Lim YC
    Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
    Patel SS; Goldfarb M
    J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer.
    Wang X; Zhu J; Li Z; Wei T
    PLoS One; 2020; 15(6):e0234843. PubMed ID: 32542018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.